<DOC>
	<DOC>NCT00435981</DOC>
	<brief_summary>This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell function in children and adolescents with type 1 diabetes with a diabetes duration less than 18 months at intervention.</brief_summary>
	<brief_title>Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Key Male and female patients between 10 and 18 years of age, diagnosed with type 1 diabetes within 18 months Fasting Cpeptide level above 0.1 nmol/l Presence of GAD65 antibodies Written informed consent (patient and parent/guardian) Key Secondary diabetes mellitus or MODY Treatment with immunosuppressants Treatment with any vaccine within 1 month prior to first Diamyd® dose or planned treatment with vaccine up to 2 months after the second Diamyd® dose Participation in other clinical trials with a new chemical entity within the previous 3 months History of certain diseases or conditions (e.g. epilepsy, anaemia, alcohole or drug abuse) HIV or hepatitis Presence of associated serious disease or condition which in the opinion of the investigator makes the patient noneligible for the study Pregnancy (or planned pregnancy within one year after 2nd administration)</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>GAD65</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>C-peptide</keyword>
	<keyword>Children</keyword>
</DOC>